Aim: The study highlighted the effect of patient-related factors on levels of pain felt by subjects during root canal treatment, as well as the association between treatment duration and pain severity.
Materials And Methods: Maxillary central incisors with either necrotic pulp or irreversibly inflamed pulp, with or without preoperative pain were studied in 160 subjects aged 18 years and above. Subject's age and gender as well as pulp status and preoperative pain status were recorded. The procedure was done using a standard protocol. Visual analog scale was used to record the level of pain felt.
Results: Those cases with irreversible pulpitis felt higher pain. None with necrotic pulp experienced intense pain, while those in the 51 to 60 year age bands had severe, unbearable or intense pain. Mild pain was a common denominator in all age bands. Pain level increased with treatment duration.
Conclusion: Except for age, the level of pain felt by subjects during RCT is significantly correlated with gender and pulp status. Furthermore, the experienced pain levels increased with treatment duration.
Clinical Significance: Clinicians should be prepared to make use of supplemental local anesthesia in women and in teeth with IP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5005/jp-journals-10024-1050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distribution of opioid analgesics by community racial/ethnic and socioeconomic profiles, 2011-2021.
Pain
January 2025
Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.
Rapid declines in opioid analgesics dispensed in American communities since 2011 raise concerns about inadequate access to effective pain management among patients for whom opioid therapies are appropriate, especially for those living in racial/ethnic minority and socioeconomically deprived communities. Using 2011 to 2021 national data from the Automated Reports and Consolidated Ordering System and generalized linear models, this study examined quarterly per capita distribution of oxycodone, hydrocodone, and morphine (in oral morphine milligram equivalents [MMEs]) by communities' racial/ethnic and socioeconomic profiles. Communities (defined by 3-digit-zip codes areas) were classified as "majority White" (≥50% self-reported non-Hispanic White population) vs "majority non-White.
View Article and Find Full Text PDFClinical and Imaging Characteristics of Posterior Scleritis in Children.
Ocul Immunol Inflamm
January 2025
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Background: Posterior scleritis (PS) is a rare phenotype of scleritis. Comprehensive epidemiological studies on PS in children are limited. We aimed to report on its clinical and imaging features in one of the largest pediatric series to date.
View Article and Find Full Text PDFHealth State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials.
Adv Ther
January 2025
Cytel, Inc., Waltham, MA, USA.
Introduction: Fabry disease (FD) is a rare lysosomal storage disorder that is associated with pain and progressive damage to the renal, cardiac, and cerebrovascular systems. Enzyme replacement therapy (ERT) is one of the treatment options for FD and the most recently approved ERT agent, pegunigalsidase alfa, has shown clinical efficacy in three phase 3 clinical trials of adults with FD: BALANCE, BRIDGE, and BRIGHT. Recent published guidelines support the mapping of health utility state data to the EuroQol-5 Dimension-3 Level (EQ-5D-3L) index to align with the preferred methodology used by the National Institute for Health and Care Excellence (NICE).
View Article and Find Full Text PDFStudy of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.
Dokl Biochem Biophys
January 2025
Center for Strategic Planning and Management of Biomedical Health Risks, Federal Medical and Biological Agency, Moscow, Russia.
Unlabelled: The association of the pathogenesis of neurodegenerative diseases, depression, anxiety, and cognitive disorders with neurotrophin-3 deficiency determines the prospect of creating drugs with a similar mechanism of action. Since the use of full-length NT-3 is limited by unsatisfactory pharmacokinetic properties, the creation of low-molecular mimetics of neurotrophin-3 that are active when administered systemically is relevant. The Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies has created a dimeric dipeptide mimetic of the 4th loop of NT-3, hexamethylenediamide bis-(N-γ-oxybutyryl-L-glutamyl-L-asparagine) with the laboratory code GTS-302, which activates TrkC and TrkB receptors.
View Article and Find Full Text PDFAnalgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.
Dokl Biochem Biophys
January 2025
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
It was previously shown that the original dipeptide mimetic of the 4th loop of neurotrophin-3 (NT-3) hexamethylenediamide bis-(N-monosuccinyl-L-asparaginyl-L-asparagine) (GTS-301), like the full-length neurotrophin, predominantly activates the tyrosine kinase receptor TrkC and has a neuroprotective effect in vitro at concentrations of 10-10 M, as well as antidiabetic (0.1 and 0.5 mg/kg) and antidepressant (5 and 10 mg/kg) effects after systemic administration in rodents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!